» Articles » PMID: 18508515

Osteopontin As a Target for Cancer Therapy

Overview
Journal Front Biosci
Specialty Biology
Date 2008 May 30
PMID 18508515
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Osteopontin (OPN) is a glycophosphoprotein cytokine that has multiple functions. OPN is expressed and secreted by various cells, and has a role in cell adhesion, chemotaxis, prevention of apoptosis, invasion, migration and anchorage-independent growth of tumor cells. Extensive research has demonstrated the pivotal participation of OPN in the regulation of cell signaling which controls neoplastic and malignant transformation. The elevated expression of OPN has been observed in a variety of cancers. OPN has been linked with tumor metastasis and signifies a poor prognosis for the patient. This review details the mechanisms by which OPN facilitates these pathological events. It will also show that gaining an understanding of the mechanism of OPN's action at a cellular level has led to the development of a number of therapeutic strategies against the cytokine. These include inhibiting its expression, antagonizing cell surface receptor activation and blocking downstream cell signaling pathways. In addition to the potential of these therapies, serum levels of OPN could be used as a diagnostic and prognostic marker. The authors propose that with further research and development, osteopontin directed treatment could greatly enhance outcomes for cancer patients.

Citing Articles

Osteopontin is a therapeutic target that drives breast cancer recurrence.

Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A Nat Commun. 2024; 15(1):9174.

PMID: 39448577 PMC: 11502809. DOI: 10.1038/s41467-024-53023-9.


Dermatopontin Influences the Development of Obesity-Associated Colon Cancer by Changes in the Expression of Extracellular Matrix Proteins.

Catalan V, Domench P, Gomez-Ambrosi J, Ramirez B, Becerril S, Mentxaka A Int J Mol Sci. 2022; 23(16).

PMID: 36012487 PMC: 9408942. DOI: 10.3390/ijms23169222.


Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications.

Amilca-Seba K, Sabbah M, Larsen A, Denis J Cancers (Basel). 2021; 13(15).

PMID: 34359694 PMC: 8345080. DOI: 10.3390/cancers13153793.


New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma.

Wang T, Zhang K Front Oncol. 2020; 10:1316.

PMID: 32923383 PMC: 7456927. DOI: 10.3389/fonc.2020.01316.


OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.

Hao C, Cui Y, Chang S, Huang J, Birkin E, Hu M Sci Rep. 2019; 9(1):18101.

PMID: 31792339 PMC: 6889187. DOI: 10.1038/s41598-019-54843-2.